{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:00:10Z","timestamp":1780452010519,"version":"3.54.1"},"reference-count":22,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T00:00:00Z","timestamp":1599955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Erenumab, a calcitonin gene\u2010related peptide (CGRP) receptor monoclonal antibody, has been well tolerated with good efficacy for the preventive treatment of episodic and chronic migraine in phase 2 and phase 3 clinical trials. Limited post\u2010market observations are available to validate these findings in a real\u2010world tertiary headache clinic population with complex comorbidities and refractory migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The goal of this study is to demonstrate the real\u2010world performance of erenumab among patients in a tertiary care headache clinic by describing patient selection, experience, and clinical characteristics after 6\u00a0months of erenumab therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective, exploratory, observational study was conducted on patients receiving at least 1 erenumab injection (70 or 140\u00a0mg). Baseline data obtained by chart review and telephone calls were compared to 6\u2010month follow\u2010up telephone calls. The primary outcome was the reduction in self\u2010reported headache days per month at baseline compared to 6\u00a0months for those with complete 6\u2010month data. The significance level was set at\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.05. Secondary analyses explored the distribution of headache severity, responder rates, Migraine Disability Assessment scores, adverse effects, ineffective preventives, comorbidities, wearing\u2010off, and discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 101 patients who consented to participate, 89.1% (90\/101) were women, and the mean age of all patients was 49\u00a0years (range, 19\u201080 years). At baseline, 94.1% (95\/101) of patients had chronic migraine, 5.0% (5\/101) had episodic migraine, and 18.8% (19\/101) had medication overuse headache. The mean (SD) number of baseline headache and migraine days per month for the entire cohort were 24.3 (8.2) and 18.2 (9.3) days, respectively. Participants had numerous comorbidities and had tried a mean of 11.2 unique oral medications and 4.8 unique medication categories before receiving erenumab, including 83.2% (84\/101) who had also received onabotulinumtoxinA. Six\u2010month post\u2010erenumab follow\u2010up data were available for 42.6% (43\/101) of participants. For these 43 participants, the number of headache days per month decreased significantly by 6.5\u00a0days from a baseline mean (SD) of 24.8 (6.47) days to 18.3 (12) days at 6\u2010month follow\u2010up (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001); similarly, the monthly migraine days decreased significantly by 8.4\u00a0days from a baseline mean of 19.1 (9.3) days to 10.7\u00a0days at 6\u2010month follow\u2010up (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001). The 50% responder rate was 34.9% (15\/43) for monthly headache days and 54.8% (23\/43) for monthly migraine days. Of all 101 participants, 28 (27.7%) discontinued erenumab, primarily because it was ineffective (39.3%, 11\/28) or because of adverse effects (42.9%, 12\/28).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This post\u2010market observational study of patient experience describes response to erenumab in a real\u2010world tertiary headache clinic with a complex patient population. Overall, these complex patients had a significant positive clinical response to erenumab, but with high rates of discontinuation. This study also noted a 1\u2010week wearing\u2010off response and high rates of constipation. Further post\u2010market studies are needed to better characterize patient selection and real\u2010world response to erenumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.13951","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T03:56:36Z","timestamp":1600314996000},"page":"2014-2025","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Real\u2010World Patient Experience With Erenumab for the Preventive Treatment of Migraine"],"prefix":"10.1111","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2556-1125","authenticated-orcid":false,"given":"Jennifer","family":"Robblee","sequence":"first","affiliation":[{"name":"Department of Neurology Barrow Neurological Institute St. Joseph\u2019s Hospital and Medical Center Phoenix AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina L.","family":"Devick","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics Department of Health Sciences Research Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Mendez","sequence":"additional","affiliation":[{"name":"Division of Neurology Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Potter","sequence":"additional","affiliation":[{"name":"Division of Neurology Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Slonaker","sequence":"additional","affiliation":[{"name":"Division of Neurology Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-1157","authenticated-orcid":false,"given":"Amaal J.","family":"Starling","sequence":"additional","affiliation":[{"name":"Division of Neurology Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03769-8"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1990.tb00236.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00232-3"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12250"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000119"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3547-3"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.799"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418776017"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13316"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418788347"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004391"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"e_1_2_8_19_1","first-page":"45","article-title":"Special report: CGRP monoclonal antibodies for chronic migraine","volume":"19","author":"Robbins L","year":"2019","journal-title":"Pract Pain Manag"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13417"},{"key":"e_1_2_8_21_1","unstructured":"Research Electronic Data Capture (REDCap).2020. Available at:https:\/\/projectredcap.org\/resources\/citations\/. Accessed February 24 2020."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00305-5"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.1.22"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhead.13951","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13951","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.13951","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.13951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:49:19Z","timestamp":1762080559000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.13951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,13]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1111\/head.13951"],"URL":"https:\/\/doi.org\/10.1111\/head.13951","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,13]]},"assertion":[{"value":"2019-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}